Insider Buying: Medicure (CVE:MPH) Director Purchases C$19,560.00 in Stock

Medicure Inc. (CVE:MPH) Director Albert David Friesen bought 16,300 shares of the firm’s stock in a transaction that occurred on Friday, June 19th. The stock was purchased at an average cost of C$1.20 per share, with a total value of C$19,560.00. Following the completion of the purchase, the director directly owned 550,767 shares of the company’s stock, valued at C$660,920.40. This represents a 3.05% increase in their position.

Albert David Friesen also recently made the following trade(s):

• On Friday, June 19th, Albert David Friesen purchased 2,000 shares of Medicure stock. The shares were purchased at an average cost of C$1.22 per share, for a total transaction of C$2,440.00.

Medicure Stock Performance

MPH stock traded up C$0.05 during trading hours on Monday, reaching C$1.25. The stock had a trading volume of 3,700 shares, compared to its average volume of 3,087. The stock has a market capitalization of C$13.04 million, a PE ratio of -1.92 and a beta of 0.54. The company has a debt-to-equity ratio of 6.34, a current ratio of 1.04 and a quick ratio of 1.28. The stock has a 50-day simple moving average of C$1.15 and a 200 day simple moving average of C$1.15. Medicure Inc. has a fifty-two week low of C$0.85 and a fifty-two week high of C$1.43.

About Medicure

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.